Octagon Capital Advisors LP
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), Octagon Capital Advisors LP reported 56 stock positions worth $822.6 million. Its top holding was Apellis Pharmaceuticals (APLS) at 20.1% of the portfolio, followed by Alpine Immune Sciences (ALPN, 6.0%) and Dianthus Therapeutics (DNTH, 5.0%). Compared with Q4 2023, it opened 33 new positions, sold out of 10, added to 8 and reduced 2. The biggest buy was a new position in Arrivent Biopharma (AVBP) and the biggest sale an exit from Cymabay Therapeutics (CBAY).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001839435
- Portfolio Value
- $822.6M (Q1 2024)
- SEC Filing
- 0001214659-24-009309 ↗ filed May 15, 2024
Holdings Value
Holdings 56 stocks · $822.6M
| APLS Apellis Pharmaceuticals Inc. | 20.06% | 2,806,980 | $165.0M | No change |
| ALPN Alpine Immune Sciences Inc. | 5.98% | 1,241,300 | $49.2M | No change |
| DNTH Dianthus Therapeutics Inc. | 5.04% | 1,380,667 | $41.4M | Add +149.2% |
| VRNA Verona Pharma Ltd. | 4.63% | 2,369,000 | $38.1M | No change |
| DYN Dyne Therapeutics Inc. | 4.29% | 1,242,945 | $35.3M | Add +56.8% |
| AVBP Arrivent Biopharma Inc. | 4.22% | 1,943,836 | $34.7M | New |
| INSM Insmed Inc. | 3.76% | 1,140,000 | $30.9M | Reduce -11.2% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.83% | 2,060,100 | $23.3M | No change |
| EYPT Eyepoint Inc. | 2.75% | 1,093,503 | $22.6M | New |
| OCUL Ocular Therapeutix Inc. | 2.68% | 2,425,000 | $22.1M | New |
| GPCR Structure Therapeutics Inc. | 2.64% | 506,604 | $21.7M | Add +22.4% |
| BBIO Bridgebio Pharma Inc. | 2.59% | 690,000 | $21.3M | Reduce -2.4% |
| MIND MEDICINE MINDMED INC | 2.46% | 2,153,000 | $20.2M | New |
| CATX Perspective Therapeutics Inc. | 2.13% | 14,718,422 | $17.5M | New |
| CRBP Corbus Pharmaceuticals Holdi | 1.93% | 405,000 | $15.9M | New |
| PRAX Praxis Precision Medicines I | 1.93% | 260,000 | $15.9M | New |
| TNYA Tenaya Therapeutics Inc. | 1.81% | 2,854,000 | $14.9M | New |
| JSPR Jasper Therapeutics Inc. | 1.79% | 500,811 | $14.7M | New |
| ANNX Annexon Inc. | 1.79% | 2,050,000 | $14.7M | No change |
| CYTK Cytokinetics Inc. | 1.65% | 194,000 | $13.6M | Add +67.2% |
| AEROVATE THERAPEUTICS INC | 1.45% | 403,685 | $11.9M | No change |
| VRDN Viridian Therapeutics Inc. | 1.32% | 620,000 | $10.9M | No change |
| GOSS Gossamer Bio Inc. | 1.32% | 9,187,883 | $10.8M | No change |
| NAMS Newamsterdam Pharma Co. NV | 1.17% | 408,000 | $9.6M | New |
| GLYCOMIMETICS INC | 1.09% | 3,000,000 | $9.0M | No change |
| IMVT Immunovant Inc. | 1.07% | 273,289 | $8.8M | No change |
| TSHA Taysha Gene Therapies Inc. | 1.06% | 3,030,000 | $8.7M | New |
| AKRO Akero Therapeutics Inc. | 1.04% | 340,000 | $8.6M | New |
| VTYX Ventyx Biosciences Inc. | 1.00% | 1,501,114 | $8.3M | New |
| CYBIN INC | 0.94% | 18,604,650 | $7.7M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.87% | 250,000 | $7.2M | New |
| MLYS Mineralys Therapeutics Inc. | 0.86% | 550,000 | $7.1M | New |
| SLN Silence Therapeutics PLC-ADR | 0.83% | 315,000 | $6.8M | New |
| PEPG Pepgen Inc. | 0.67% | 376,117 | $5.5M | New |
| VINCERX PHARMA INC | 0.62% | 1,000,000 | $5.1M | New |
| NUVB Nuvation Bio Inc. | 0.61% | 1,374,870 | $5.0M | Add +37.5% |
| PHAT Phathom Pharmaceuticals Inc. | 0.59% | 455,000 | $4.8M | Add +810.0% |
| MERSANA THERAPEUTICS INC | 0.54% | 1,000,000 | $4.5M | New |
| TERN Terns Pharmaceuticals Inc. | 0.50% | 625,000 | $4.1M | New |
| FATE Fate Therapeutics Inc. | 0.46% | 520,800 | $3.8M | New |
| RENEO PHARMACEUTICALS INC | 0.45% | 2,250,000 | $3.7M | No change |
| ANAB Anaptysbio Inc. | 0.45% | 165,000 | $3.7M | Add +37.5% |
| SANA Sana Biotechnology Inc. | 0.44% | 360,800 | $3.6M | New |
| ANTX AN2 Therapeutics Inc. | 0.44% | 1,103,000 | $3.6M | Add +66.0% |
| ALLO Allogene Therapeutics Inc. | 0.39% | 720,000 | $3.2M | New |
| ALLOVIR INC | 0.39% | 4,200,000 | $3.2M | New |
| VERU Veru Inc. | 0.32% | 3,800,000 | $2.7M | No change |
| RAPT THERAPEUTICS INC | 0.32% | 292,000 | $2.6M | No change |
| NKTX Nkarta Inc. | 0.32% | 240,000 | $2.6M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.31% | 250,000 | $2.6M | New |
| PSTX Poseida Therapeutics Inc. | 0.29% | 736,000 | $2.3M | New |
| IPSC Century Therapeutics Inc. | 0.27% | 540,000 | $2.3M | New |
| ACET Adicet Bio Inc. | 0.22% | 767,799 | $1.8M | New |
| ATYR Atyr Pharma Inc. | 0.17% | 700,000 | $1.4M | New |
| AUTL Autolus Therapeutics PLC | 0.14% | 176,000 | $1.1M | New |
| CABA Cabaletta Bio Inc. | 0.11% | 52,000 | $887K | New |
Options reported separately and not counted above: APLS calls ($11.8M).
Portfolio Sells Q4 2023 → Q1 2024
| CBAY Cymabay Therapeutics Inc. | Sold out | 0.00% | −10.10 |
| RCUS Arcus Biosciences Inc. | Sold out | 0.00% | −5.71 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −4.49 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −4.48 |
| INSM Insmed Inc. | Reduce -11.2% | 3.76% | −2.61 |
| BBIO Bridgebio Pharma Inc. | Reduce -2.4% | 2.59% | −1.97 |
| GRCL Gracell Biotechnologies-ADR | Sold out | 0.00% | −0.96 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −0.56 |
| INZY Inozyme Pharma Inc. | Sold out | 0.00% | −0.27 |
| XLO Xilio Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −0.12 |
| ACRS Aclaris Therapeutics Inc. | Sold out | 0.00% | −0.02 |
Portfolio Buys Q4 2023 → Q1 2024
| AVBP Arrivent Biopharma Inc. | New | 4.22% | +4.22 |
| DNTH Dianthus Therapeutics Inc. | Add +149.2% | 5.04% | +4.11 |
| EYPT Eyepoint Inc. | New | 2.75% | +2.75 |
| OCUL Ocular Therapeutix Inc. | New | 2.68% | +2.68 |
| DYN Dyne Therapeutics Inc. | Add +56.8% | 4.29% | +2.60 |
| MIND MEDICINE MINDMED INC | New | 2.46% | +2.46 |
| CATX Perspective Therapeutics Inc. | New | 2.13% | +2.13 |
| CRBP Corbus Pharmaceuticals Holdi | New | 1.93% | +1.93 |
| PRAX Praxis Precision Medicines I | New | 1.93% | +1.93 |
| TNYA Tenaya Therapeutics Inc. | New | 1.81% | +1.81 |
| JSPR Jasper Therapeutics Inc. | New | 1.79% | +1.79 |
| NAMS Newamsterdam Pharma Co. NV | New | 1.17% | +1.17 |
| TSHA Taysha Gene Therapies Inc. | New | 1.06% | +1.06 |
| AKRO Akero Therapeutics Inc. | New | 1.04% | +1.04 |
| VTYX Ventyx Biosciences Inc. | New | 1.00% | +1.00 |
| CYBIN INC | New | 0.94% | +0.94 |
| ARWR Arrowhead Pharmaceuticals Inc. | New | 0.87% | +0.87 |
| MLYS Mineralys Therapeutics Inc. | New | 0.86% | +0.86 |
| SLN Silence Therapeutics PLC-ADR | New | 0.83% | +0.83 |
| PEPG Pepgen Inc. | New | 0.67% | +0.67 |
| VINCERX PHARMA INC | New | 0.62% | +0.62 |
| MERSANA THERAPEUTICS INC | New | 0.54% | +0.54 |
| PHAT Phathom Pharmaceuticals Inc. | Add +810.0% | 0.59% | +0.51 |
| TERN Terns Pharmaceuticals Inc. | New | 0.50% | +0.50 |
| FATE Fate Therapeutics Inc. | New | 0.46% | +0.46 |
| SANA Sana Biotechnology Inc. | New | 0.44% | +0.44 |
| ALLO Allogene Therapeutics Inc. | New | 0.39% | +0.39 |
| ALLOVIR INC | New | 0.39% | +0.39 |
| NUVB Nuvation Bio Inc. | Add +37.5% | 0.61% | +0.37 |
| NKTX Nkarta Inc. | New | 0.32% | +0.32 |
| BBOT Bridgebio Oncology Therapeut | New | 0.31% | +0.31 |
| PSTX Poseida Therapeutics Inc. | New | 0.29% | +0.29 |
| IPSC Century Therapeutics Inc. | New | 0.27% | +0.27 |
| ACET Adicet Bio Inc. | New | 0.22% | +0.22 |
| ATYR Atyr Pharma Inc. | New | 0.17% | +0.17 |
| AUTL Autolus Therapeutics PLC | New | 0.14% | +0.14 |
| CABA Cabaletta Bio Inc. | New | 0.11% | +0.11 |
| CYTK Cytokinetics Inc. | Add +67.2% | 1.65% | +0.10 |
| ANAB Anaptysbio Inc. | Add +37.5% | 0.45% | +0.04 |
| GPCR Structure Therapeutics Inc. | Add +22.4% | 2.64% | −0.06 |
| ANTX AN2 Therapeutics Inc. | Add +66.0% | 0.44% | −1.74 |
Options Activity Q4 2023 → Q1 2024
| APLS Apellis Pharmaceuticals Inc. | call | New | 200,000 | $11.8M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 26 | $1.1B | DNTH, DFTX, ABVX, COGT, ALMS |
| Q1 2026 | 29 | $903.6M | DNTH, COGT, ABVX, ALMS, DFTX |
| Q4 2025 | 26 | $798.8M | ABVX, DNTH, COGT, TSHA, GOSS |
| Q3 2025 | 25 | $640.2M | ABVX, DNTH, GOSS, COGT, AVBP |
| Q2 2025 | 29 | $455.3M | DNTH, AVBP, VRNA, TSHA, SPRY |
| Q1 2025Amended | 33 | $460.1M | APLS, DNTH, AVBP, TRVI, CNTA |
| Q4 2024 | 30 | $587.1M | APLS, AVBP, DNTH, CNTA, VRNA |
| Q3 2024 | 40 | $623.9M | APLS, VRNA, GPCR, DNTH, AVBP |
| Q2 2024 | 44 | $606.1M | APLS, DNTH, GPCR, INSM, DYN |
| Q1 2024 | 56 | $822.6M | APLS, ALPN, DNTH, VRNA, DYN |